ReviewInternational urology and nephrology2026

SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials.

Leonardo Spatola et al.PubMed ↗Publisher ↗

No numbers read from the abstract.